Could your own cells ease knee arthritis pain?

NCT ID NCT02844751

Recruiting now Disease control Sponsor: VivaTech International, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a treatment made from a patient's own bone marrow cells (StroMed) combined with platelet-rich plasma can safely reduce pain and inflammation from knee osteoarthritis. The trial plans to enroll 4,000 people with moderate to severe knee arthritis. Researchers will measure changes in pain, function, and cartilage growth using surveys and MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: StroMed (a cell concentrate from the patient's own bone marrow) combined with platelet-rich plasma (PRP)
What this could lead to: If successful, this could offer a new way to reduce pain and possibly regrow cartilage in people with knee osteoarthritis, potentially delaying or avoiding knee replacement surgery.
What could go wrong: This is an early-phase, open-label study with no placebo group, so results may be influenced by bias. The treatment is experimental and not yet proven; larger studies are needed to confirm safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOARTHRITIS

Contacts and locations

Locations

VivaTech International, Inc.
RECRUITING

Grove City, Pennsylvania, 16127, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.